未登录
分享
收藏
分享
收藏
分享
收藏
分享
收藏Butterfly-effect nano-platforms for cascade immune amplification and tumor clearance through multi-modal therapy and immune sensitization
Chen, Haoyu; Kong, Xiaoying; Yan, Jiahui; Wang, Tianyi; Lv, Yaqian; Zhang, Fenglang; Liu, Danping; Qu, Yingshan; Fu, Jun; Han, Wei; Shi, Jinsheng
分享
收藏Activated Immune System Determines In Vivo Anti-Tumor Effect of Phototherapy by Inhibiting Cancer-Associated Fibroblasts激活的免疫系统通过抑制癌症相关成纤维细胞决定光疗的体内抗肿瘤作用
Ding, Mengchao; Chen, Haoyu; Guimaraes, Carlos F.; Reis, Rui L.; Wu, Lijuan; Zhang, Fenglan; Lv, Yaqian; Wang, Tianyi; Zhou, Qihui; Shi, Jinsheng; Kong, Xiaoying
分享
收藏Three-dimension chitosan hydrogel loading melanin composite nanoparticles for wound healing by anti-bacteria, immune activation and macrophage autophagy promotion三维壳聚糖水凝胶负载黑色素复合纳米粒用于创面愈合的抗菌、免疫激活和巨噬细胞自噬促进作用
Kong, Xiaoying; Chen, Haoyu; Li, Fuqiang; Zhang, Fenglan; Jiang, Yuping; Song, Junyao; Sun, Yuanliang; Zhao, Bin; Shi, Jinsheng
分享
收藏
分享
收藏
分享
收藏
分享
收藏Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial
Cheng, Ying; Han, Liang; Wu, Lin; Chen, Jun; Sun, Hongmei; Wen, Guilan; Ji, Yinghua; Dvorkin, Mikhail; Shi, Jianhua; Pan, Zhijie; Shi, Jinsheng; Wang, Xicheng; Bai, Yuansong; Melkadze, Tamar; Pan, Yueyin; Min, Xuhong; Viguro, Maksym; Li, Xingya; Zhao, Yanqiu; Yang, Junquan; Makharadze, Tamta; Arkania, Ekaterine; Kang, Wenying; Wang, Qingyu; Zhu, Jun
分享
收藏Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study
Lin, Ningjing; Zhang, Mingzhi; Bai, Hai; Liu, Hui; Cui, Jie; Ke, Xiaoyan; Zhang, Huilai; Liu, Lihong; Yan, Dongmei; Jiang, Yongsheng; Zang, Aimin; Qi, Junyuan; Wang, Li; Liu, Zhuogang; Xu, Bing; Zhang, Ying; Zhang, Zhihui; Zhao, Xielan; Hu, Chunhong; Yang, Shenmiao; Zhou, Hui; Shi, Jinsheng; Shao, Zonghong; Xiang, Ying; Zhu, Jiman; Song, Yuqin; Zhu, Jun
分享
收藏
分享
收藏
分享
收藏
分享
收藏Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial
Shi, Yuankai; Lei, Kaijian; Jia, Yuming; Ni, Bingqiang; He, Zhiyong; Bi, Minghong; Wang, Xicheng; Shi, Jianhua; Zhou, Ming; Sun, Qian; Wang, Guolei; Chen, Dongji; Shu, Yongqian; Liu, Lianke; Guo, Zhongliang; Liu, Yong; Yang, Junquan; Wang, Ke; Xiao, Ke; Wu, Lin; Yi, Tienan; Sun, Debin; Kang, Mafei; Ma, Tianjiang; Mao, Yimin; Shi, Jinsheng; Tang, Tiegang; Wang, Yan; Xing, Puyuan; Lv, Dongqing; Liao, Wangjun; Luo, Zhiguo; Wang, Bin; Wu, Xiaohong; Zhu, Xiaoli; Han, Shuhua; Guo, Qisen; Liu, Rongyu; Lu, Zhiwei; Zhang, Jianyong; Fang, Jian; Hu, Changlu; Ji, Yinghua; Liu, Guolong; Lu, Hong; Wu, Dedong; Zhang, Junhong; Zhu, Shuyang; Liu, Zheng; Qiu, Wensheng; Ye, Feng; Yu, Yan; Zhao, Yanqiu; Zheng, Qinhong; Chen, Jun; Pan, Zhanyu; Zhang, Yiping; Lian, Wenjuan; Jiang, Bo; Qiu, Bo; Zhang, Guojun; Zhang, Hua; Chen, Yanju; Chen, Yuan; Duan, Hongbing; Li, Manxiang; Liu, Shengming; Ma, Lijun; Pan, Hongming; Yuan, Xia; Yuan, Xueli; Zheng, Yulong; Gao, Emei; Zhao, Li; Wang, Shumin; Wu, Can
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏